Vaginal mesh is a net-like synthetic implant, most commonly made from polypropylene, that surgeons place in the pelvis to reinforce weakened tissue in women with pelvic organ prolapse or stress urinary incontinence. The controversy erupted because these devices entered the market without clinical trial data, and a significant minority of women who received them developed severe, sometimes irreversible complications including chronic pain, mesh erosion through vaginal tissue, and painful intercourse. More than 73,000 patients have filed product liability claims in the United States alone, and several countries have banned or sharply restricted transvaginal mesh placement.
What the Mesh Is Made of and What It Is Meant to Do
Pelvic organ prolapse occurs when the muscles and connective tissue supporting the bladder, uterus, or rectum weaken enough that one or more of those organs bulge into or through the vaginal wall. It is a common condition: the lifetime risk of needing at least one surgical intervention is close to one in ten women.1PubMed Central. To mesh or not to mesh: a review of pelvic organ reconstructive surgery The traditional surgical fix, called native tissue repair, uses a woman’s own tissue to restore the pelvic anatomy. But in the 1990s, the rate of prolapse returning after this kind of surgery was believed to be as high as 30 to 50 percent, which drove surgeons to look for something sturdier.
The idea behind mesh was straightforward: a permanent synthetic scaffold would give the weakened tissue structural support that the body’s own collagen could not reliably provide. Most commercial meshes are woven or knitted from polypropylene fibers. They come in different weave patterns, pore sizes, and weights, and these structural properties strongly influence how the body tolerates the implant.2PubMed. Biomechanical properties of synthetic surgical meshes for pelvic prolapse repair A separate category of mesh, the mid-urethral sling, is a narrow strip placed under the urethra to treat stress urinary incontinence, and its safety profile has been somewhat different from the larger prolapse meshes.
How the Devices Reached Patients Without Clinical Trials
Much of the controversy traces back to how vaginal mesh was approved. In the United States, medical devices can reach the market through the FDA’s 510(k) pathway, which requires a manufacturer to show that a new device is “substantially equivalent” to one already on the market. This creates a chain-of-equivalency problem: each new product references an older product, which referenced an older product still, and none of them may have been tested in clinical trials with patients. A systematic review of the FDA approval process found that vaginal mesh devices consistently used this less demanding 510(k) route rather than the more rigorous Premarket Approval pathway that would have required clinical data.3PubMed Central. Trials of transvaginal mesh devices for pelvic organ prolapse: a systematic database review of the US FDA approval process
Mesh kits designed specifically for transvaginal prolapse repair entered the U.S. market in 2005 without clinical safety or efficacy data.4PubMed. Transvaginal mesh: a historical review and update of the current state of affairs in the United States Within a few years, reports of major and minor complications started piling up, which led the FDA to issue a public health notification in July 2011 raising safety concerns about vaginal mesh for prolapse.5PubMed. Pelvic mesh complications in women before and after the 2011 FDA public health notification The agency later reclassified these devices to Class III, the highest risk category, and in 2019 ordered manufacturers to stop selling and distributing transvaginal mesh for prolapse repair altogether. That order did not apply to mesh placed through abdominal surgery or to mid-urethral slings for incontinence.
What Complications Look Like
The complications that drove the controversy are varied, but they cluster into a few main categories: mesh exposure (sometimes called erosion), chronic pain, and painful intercourse. Mesh exposure happens when the implant works its way through the vaginal wall and becomes visible or palpable inside the vagina, sometimes extending into the bladder or bowel. In the worst cases, it causes perforation of nearby organs.6Obstetrics, Gynaecology & Reproductive Medicine. The management of mesh complications
Mesh contraction is a particularly distressing complication. When the body lays down scar tissue around the implant, the mesh can shrink and pull the surrounding vagina with it. A study of women who developed mesh contraction found that every single patient reported severe vaginal pain aggravated by movement, and all sexually active women reported dyspareunia. Mesh erosion was present in about half the cases, and vaginal tightness or shortening was common.7PubMed. Vaginal mesh contraction: definition, clinical presentation, and management Research in animal models has shown that when mesh physically deforms after implantation, it triggers two problems: tissue breakdown where the mesh pushes through the vaginal lining, and proliferation of scar-forming cells that cause pain.8PubMed Central. Mesh deformation: A mechanism underlying polypropylene prolapse mesh complications in vivo
Data from the PROSPECT trial, a large randomized study, put numbers on some of these harms. At two years, severe dyspareunia occurred in about 13 percent of women who received a mesh kit, compared with roughly 5 percent of women who had native tissue repair. New-onset vaginal tightness occurred in about 4 percent of mesh kit recipients versus under 2 percent with native tissue.9PubMed Central. How common are complications following polypropylene mesh, biological xenograft and native tissue surgery for pelvic organ prolapse? A secondary analysis from the PROSPECT trial
Why the Body Sometimes Rejects the Mesh
Polypropylene is technically inert, but placing it in vaginal tissue does not mean the body ignores it. When mesh is implanted, the immune system surrounds each fiber with macrophages, the cleanup cells of the immune system. In women who develop complications, research has found that these macrophages tend to be heavily skewed toward a pro-inflammatory type, and the tissue around the mesh shows elevated levels of enzymes that break down collagen and extracellular matrix.10PubMed Central. Host response to synthetic mesh in women with mesh complications In cases where the mesh erodes through the vaginal wall, the concentration of macrophages around the fibers is significantly higher than in mesh that stays in place without problems.11PubMed. Foreign body reaction in vaginally eroded and noneroded polypropylene suburethral slings in the female: a case series
Explanted tissue from women with complications typically shows a dense capsule of fibrous scar tissue with heavy immune cell infiltration, which suggests the immune response plays a central role in complications, not just the mechanical properties of the mesh itself. The vaginal environment is part of the problem: it is a biologically active space with microorganisms, mechanical stresses from movement and intercourse, and hormonal changes, all of which interact with an implant in ways that differ from, say, mesh placed on the abdominal wall for hernia repair.12PubMed Central. Host–biomaterial interactions in mesh complications after pelvic floor reconstructive surgery
Transvaginal Placement Versus Abdominal Placement
Not all mesh procedures carry the same risk, and this distinction matters. Mesh placed through the vagina for prolapse repair (transvaginal mesh repair, or TVMR) has consistently been the highest-risk approach. Mesh placed through the abdomen, either via open surgery or laparoscopy (sacrocolpopexy), appears significantly safer. A large comparative study found that the rate of mesh requiring removal or revision was about 5 percent for transvaginal placement, compared with roughly 1 to 2 percent for abdominal or laparoscopic sacrocolpopexy. Pelvic pain was common across all surgical approaches, reported by roughly 16 to 23 percent of patients regardless of technique.13PubMed. Mesh complications and failure rates after transvaginal mesh repair compared with abdominal or laparoscopic sacrocolpopexy and to native tissue repair in treating apical prolapse
This is why regulators have drawn a line between the two approaches. When the FDA ordered transvaginal mesh for prolapse off the market, it did not ban mesh used in abdominal sacrocolpopexy, which remains a standard procedure for vault prolapse. The distinction matters for patients: a woman being offered a sacrocolpopexy is not in the same risk category as one who would have received a transvaginal mesh kit.
Does Mesh Actually Work Better Than Traditional Surgery?
The frustrating answer is: anatomically, yes, but the patient may not feel much difference, and the tradeoff is more complications. A large Cochrane review pooling data from dozens of randomized trials found that women who received transvaginal mesh were less likely to have recurrent prolapse on examination and somewhat less likely to be aware of their prolapse compared with women who had native tissue repair. The rate of needing repeat surgery for prolapse was also lower in the mesh group.14PubMed Central. Transvaginal mesh or grafts or native tissue repair for vaginal prolapse
A separate meta-analysis found a similar pattern: mesh produced higher anatomical cure rates and slightly greater patient satisfaction, with no difference in reoperation rates overall, but it came with a higher incidence of both early and late complications.15PubMed. Native tissue repair (NTR) versus transvaginal mesh interventions for the treatment of anterior vaginal prolapse: Systematic review and meta-analysis Meanwhile, the old statistic that drove mesh adoption — that 30 to 50 percent of native tissue repairs fail — has been revised downward. More recent estimates put the reoperation rate after native tissue repair closer to 10 percent, a much less alarming number that weakens the original case for widespread mesh use.1PubMed Central. To mesh or not to mesh: a review of pelvic organ reconstructive surgery In other words, the problem mesh was meant to solve was not as large as surgeons initially believed.
Mid-Urethral Slings Are a Different Story
Slings for stress urinary incontinence use a narrow polypropylene strip placed under the urethra, and they have generally fared better than the larger mesh kits for prolapse. Most regulatory bans and restrictions have exempted these devices. However, they are not complication-free. A large cohort study tracking long-term outcomes found that the 10-year risk of needing sling revision was about 7 percent, rising to roughly 8 percent at 15 years. Nearly half of those revisions were related to mesh exposure. The risk of needing repeat surgery for incontinence was higher still, around 14.5 percent at 10 years and about 18 percent at 15 years. Younger women, particularly those under 30, faced elevated risks for both revision and repeat surgery.16PubMed Central. Long-term outcomes following midurethral mesh sling surgery for stress urinary incontinence
In the UK, retropubic mid-urethral slings inserted in a bottom-up technique have been reinstated as a treatment option alongside non-mesh alternatives like colposuspension and autologous fascial slings. Transobturator slings, however, remain restricted.17PubMed Central. The international discussion and the new regulations concerning transvaginal mesh implants in pelvic organ prolapse surgery
When Mesh Needs to Come Out
Removing mesh is often harder than putting it in. Once implanted, the body incorporates the mesh into surrounding tissue with scar formation, so extraction becomes a delicate surgery with its own risks. Experts remain divided on whether partial or complete removal is better. Focal areas of exposure or pain can sometimes be managed with partial mesh removal, which carries lower complication rates. But many patients who undergo partial removal ultimately need further procedures. Complete excision is considered for women with widespread vaginal pain, large areas of exposure, or mesh pushing into the bladder or bowel, but it carries the risk of recurrent incontinence or prolapse once the structural support is gone.18PubMed Central. Management of vaginal mesh exposure: A systematic review The surgical approach continues to evolve, with some specialists advocating for complete removal while others prefer more conservative excision depending on the clinical picture.19PubMed. An update on research and outcomes in surgical management of vaginal mesh complications
Global Regulatory Responses
The regulatory backlash has been worldwide but uneven. In Australia, transvaginal meshes for prolapse have been removed from the market entirely, though suburethral slings for incontinence remain available. New Zealand has followed a similar approach. In Canada, a 2019 safety review led to transvaginal meshes for posterior repair being pulled, with anterior and apical meshes restricted to patients at high risk of recurrence or those without suitable alternatives; all three companies with active licenses subsequently withdrew their products. In the UK, an independent review in 2018 called for a halt on transvaginal mesh, and that pause largely remains in place. Abdominal and laparoscopic sacrocolpopexy using mesh can still be performed in most of these countries.17PubMed Central. The international discussion and the new regulations concerning transvaginal mesh implants in pelvic organ prolapse surgery
The Human Cost Beyond Physical Symptoms
Mesh complications do not stay neatly in the category of surgical side effects. Qualitative research with affected women reveals experiences that go well beyond pain and functional problems. Women described the psychological impact of mesh complications as traumatic, reporting heightened anxiety and, in some cases, fears relating to suicidal thoughts. Intimate relationships suffered from reduced sexual functioning and the emotional toll of chronic pain.20PubMed Central. When things go wrong: experiences of vaginal mesh complications
The economic burden is also real. In one study, affected women missed a median of 12 months of work or school because of their complications, and about a third reported that their family income dropped due to lost productivity.21PubMed. The Disability Impact and Associated Cost per Disability in Women Who Underwent Surgical Revision of Transvaginal Mesh Kits for Prolapse Repair Many women reported feeling dismissed by doctors who did not connect their symptoms to the mesh, and online communities became a crucial source of recognition. Hearing other patients describe identical symptoms was, for many, the first moment they realized the mesh could be the cause of their problems.22The Lancet. Experiences of living with complications attributed to vaginal mesh surgery: a qualitative study
The Surgeon Factor
One underappreciated variable in mesh outcomes is surgeon experience. A study examining the link between surgical volume and complications found that the risk of reoperation for mesh complications was meaningfully lower only for patients of very high-volume surgeons — about 3 percent compared with roughly 5 percent for surgeons who performed fewer procedures.23PubMed. Surgeon Experience and Complications of Transvaginal Prolapse Mesh This matters because transvaginal mesh procedures were widely adopted by surgeons across a range of experience levels, and the kits were sometimes marketed as making the surgery easier. The data suggest that even in skilled hands, the complication rate was not trivial, and in less experienced hands it was worse.
Alternatives That Do Not Involve Mesh
With transvaginal mesh for prolapse now off the table in much of the world, the options for women with pelvic floor disorders have shifted. For prolapse, native tissue repair remains the standard vaginal approach, and abdominal sacrocolpopexy with mesh is still used for specific situations, particularly vault prolapse. Pelvic floor physiotherapy is a non-surgical first-line option that helps many women manage mild to moderate prolapse.
For stress urinary incontinence, the alternatives to mesh slings include urethral bulking agent injections, which are the lowest-risk option and can be performed under local anesthesia in an outpatient setting, making them suitable even for frail or elderly patients. Autologous fascial slings, which use a strip of the patient’s own tissue harvested from the abdominal wall or thigh, have evolved into a less invasive technique with a likely better safety profile than earlier versions. Colposuspension, an established surgical procedure that lifts the tissues near the bladder neck, can be done through open or laparoscopic approaches.24Continence. Non-mesh stress incontinence surgery review: Bulking agents, autologous fascial slings and colposuspension
A health-economic analysis found that under standard assumptions, mesh-augmented anterior repair for prolapse was not cost-effective at five years, with the extra cost of the mesh device itself plus the expense of treating erosion largely erasing any anatomical benefit.25PubMed. A decision-analytic Markov model to compare the cost-utility of anterior repair augmented with synthetic mesh compared with non-mesh repair in women with surgically treated prolapse
The Legal Fallout
The mesh controversy became one of the largest mass tort actions in U.S. legal history. Following FDA communications about safety concerns, more than 73,000 patients filed product liability claims against mesh manufacturers.26Female Pelvic Medicine & Reconstructive Surgery. The Truth Behind Transvaginal Mesh Litigation: Devices, Timelines, and Provider Characteristics Settlements have totaled billions of dollars. The lawsuits have centered on claims that manufacturers knew or should have known about the risks, that the devices were inadequately tested before going to market, and that marketing materials understated complications. For many women, litigation was not primarily about money but about accountability — a formal acknowledgment that something went wrong.
What Researchers Are Working on Now
The problems with polypropylene mesh have not killed interest in implantable pelvic supports; they have redirected it. Researchers are working on bioresorbable meshes — materials designed to provide temporary scaffolding while the body builds its own tissue, then gradually dissolve. One promising approach combines tropoelastin, a natural protein that gives tissues their elasticity, with a degradable synthetic polymer. When tested in an animal model of prolapse, this type of mesh showed strong tissue integration, healthy collagen growth, and an immune response dominated by anti-inflammatory rather than pro-inflammatory macrophages.27PubMed Central. A novel tropoelastin-based resorbable surgical mesh for pelvic organ prolapse repair
Broader research is exploring both synthetic and natural biopolymers, surface coatings that can release therapeutic agents to reduce inflammation, and advanced manufacturing methods including 4D printing.28PubMed. Emerging materials and technologies for advancing bioresorbable surgical meshes Computational modeling is also playing a growing role, allowing researchers to simulate how a mesh will behave under real-world mechanical stresses before it goes into a patient, with the goal of personalizing implants to individual anatomy.29PubMed. Biodegradable mesh implants for prolapse repair: Advances in computational modelling and experimental validation None of these technologies are ready for routine clinical use yet, but they represent a fundamentally different design philosophy from the permanent polypropylene implants that caused so much harm: support the tissue while it heals, then get out of the way.